The Biomembrane Institute

Otsuka America Pharmaceutical, Inc.

Oncomembrane, Inc.

Shigeyuki Kawa

Sen-Itiroh Hakomori

Yasuyuki Igarashi

Yoshito Sadahira

Fuqiang Ruan

Fugiang Ruan

A method of inhibiting tumor cell chemotactic motility and/or chemoinvasion, a method of inhibiting phagokinetic activity of tumor cells and neutrophils, a method of inhibiting tumor cell metastasis and a method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising contacting the cells or administering to a host in need of treatment an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives is also described.

Method for inhibition of cell motility by sphingosine-1-phosphate and

A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising administering to a host in need of treatment an inflammation inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives.

Sphingosine-1-phosphate essentially free of L-threo isomer

Method for inhibition of cell motility by sphingosine-1-phosphate, its

Growing community of inventors

Seattle, WA, United States of America

Shigeyuki Kawa